Total Payments
$656.94
2024 Payments
$548.56
Companies
11
Transactions
23
Medicare Patients
1,437
Medicare Billing
$263,289
Payment Breakdown by Category
Food & Beverage$656.94 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $656.94 | 23 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Melinta Therapeutics, LLC | $132.91 | 2 | $0 (2024) |
| La Jolla Pharmaceutical Company | $127.26 | 6 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $108.38 | 1 | $0 (2023) |
| Insmed, Inc. | $63.57 | 3 | $0 (2024) |
| Merck Sharp & Dohme LLC | $48.26 | 2 | $0 (2024) |
| Shionogi Inc | $42.65 | 2 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $38.11 | 2 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $33.57 | 2 | $0 (2024) |
| AIMMUNE THERAPEUTICS, INC. | $26.46 | 1 | $0 (2024) |
| Astellas Pharma US Inc | $21.97 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $548.56 | 22 | Melinta Therapeutics, LLC ($132.91) |
| 2023 | $108.38 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($108.38) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 11/12/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $111.32 | General |
| Category: ANTIFUNGALS | ||||||
| 11/12/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 11/07/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Infectious Diseases | ||||||
| 10/29/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: ANTIBIOTIC | ||||||
| 10/17/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/03/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/30/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: ANTIFUNGALS | ||||||
| 09/24/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 09/12/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: ANTIBIOTIC | ||||||
| 09/05/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 08/22/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: Respiratory | ||||||
| 07/25/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $25.37 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/23/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: GI | ||||||
| 07/11/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Respiratory | ||||||
| 07/02/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 06/28/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/27/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 06/14/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/28/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 05/02/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/16/2023 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $108.38 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 262 | 512 | $231,010 | $50,594 |
| 2022 | 7 | 300 | 654 | $272,388 | $59,778 |
| 2021 | 8 | 446 | 860 | $327,806 | $72,694 |
| 2020 | 8 | 429 | 928 | $345,672 | $80,224 |
Total Patients
1,437
Total Services
2,954
Medicare Billing
$263,289
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 57 | 163 | $66,284 | $15,358 | 23.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 26 | 65 | $51,510 | $11,132 | 21.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 73 | 167 | $45,230 | $10,357 | 22.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 41 | $27,579 | $5,653 | 20.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 35 | 36 | $17,370 | $3,735 | 21.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 25 | $16,177 | $3,269 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 15 | $6,860 | $1,089 | 15.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 81 | 288 | $105,567 | $23,378 | 22.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 18 | 59 | $46,551 | $10,280 | 22.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 83 | 183 | $46,660 | $10,277 | 22.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 41 | 42 | $29,904 | $6,631 | 22.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 34 | $21,910 | $4,384 | 20.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 35 | 36 | $17,436 | $3,860 | 22.1% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 12 | 12 | $4,360 | $967.54 | 22.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 126 | 419 | $154,674 | $34,496 | 22.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 121 | 225 | $57,728 | $12,992 | 22.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 80 | 82 | $58,872 | $12,889 | 21.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 59 | 61 | $29,874 | $6,465 | 21.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 17 | $10,027 | $2,375 | 23.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 19 | $8,100 | $1,568 | 19.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 15 | 15 | $5,484 | $1,231 | 22.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 16 | 22 | $3,047 | $678.04 | 22.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 116 | 423 | $153,377 | $36,146 | 23.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 95 | 106 | $74,752 | $17,679 | 23.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 110 | 272 | $68,952 | $16,072 | 23.3% |
About Dr. Guy El Helou, M.D
Dr. Guy El Helou, M.D is a Infectious Disease healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2016. The National Provider Identifier (NPI) number assigned to this provider is 1255783528.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Guy El Helou, M.D has received a total of $656.94 in payments from pharmaceutical and medical device companies, with $548.56 received in 2024. These payments were reported across 23 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($656.94).
As a Medicare-enrolled provider, El Helou has provided services to 1,437 Medicare beneficiaries, totaling 2,954 services with total Medicare billing of $263,289. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Gainesville, FL
- Active Since 07/11/2016
- Last Updated 01/27/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1255783528
Products in Payments
- Rezzayo (Drug) $132.91
- XERAVA (Drug) $127.26
- LIVTENCITY (Drug) $108.38
- Arikayce (Drug) $63.57
- Fetroja (Drug) $42.65
- NUZYRA (Drug) $38.11
- REBYOTA (Biological) $33.57
- VOWST (Biological) $26.46
- PREVYMIS (Drug) $25.37
- DIFICID (Drug) $22.89
- Cresemba (Drug) $21.97
- VIBATIV (Drug) $13.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Gainesville
Lennox Archibald, Md, MD
Infectious Disease — Payments: $2.9M
Infectious Disease $2.9M
Dr. Cornelius Clancy, Md, MD
Infectious Disease — Payments: $166,876
Infectious Disease $166,876
Adam Bressler, M.d, M.D
Infectious Disease — Payments: $123,008
Infectious Disease $123,008
Wendy Garlington, Md, MD
Infectious Disease — Payments: $1,427
Infectious Disease $1,427
Gary Wang, Md, Phd, MD, PHD
Infectious Disease — Payments: $850.64
Infectious Disease $850.64
Marie Kima, M.d, M.D
Infectious Disease — Payments: $749.97
Infectious Disease $749.97